ArticlePLoS genetics2011
Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans.
Article in PLoS genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Association of kidney structure-related gene variants with type 2 diabetes-attributed end-stage kidney disease in African Americans.Human genetics · 2016Pooled it
- Genome-Wide Association and Trans-ethnic Meta-Analysis for Advanced Diabetic Kidney Disease: Family Investigation of Nephropathy and Diabetes (FIND).PLoS genetics · 2015Pooled it
- Association testing of previously reported variants in a large case-control meta-analysis of diabetic nephropathy.Diabetes · 2012Pooled it
- Gene modification: Exploring the potential in treating kidney diseases.Pharmacological research · 2026Review
- Artificial intelligence-powered prediction of diabetic complications: from clinical data to molecular omics.Briefings in bioinformatics · 2026Article
- Bioinformatics and Next-Generation Data Analysis for Identification of Genes and Molecular Pathways Involved in Subjects with Diabetes and Obesity.Medicina (Kaunas, Lithuania) · 2023Article
- Genetic and epigenetic background of diabetic kidney disease.Frontiers in endocrinology · 2023Review
- High FRMD3 expression is prognostic for worse survival in rectal cancer patients treated with CCRT.International journal of clinical oncology · 2021Article
- Association of single-nucleotide polymorphism on chromosome 9 and ischemic stroke in Heilongjiang province in China.International journal of clinical and experimental pathology · 2021Article
- Genetic susceptibility of hypertension-induced kidney disease.Physiological reports · 2021Review
- Kidney Disease-AssociatedJournal of the American Society of Nephrology : JASN · 2020Article
- Apolipoprotein L1 Gene Testing Comes of Age.Kidney360 · 2020Article
- Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African Americans.Human genomics · 2019Article
- Genetic and Epigenetic Studies in Diabetic Kidney Disease.Frontiers in genetics · 2019Review
- APOL1-Associated Nephropathy: A Key Contributor to Racial Disparities in CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2018Review
- APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.Trends in molecular medicine · 2018Review
- Progressive glomerular and tubular damage in sickle cell trait and sickle cell anemia mouse models.Translational research : the journal of laboratory and clinical medicine · 2018Article
- A Putative Role of Apolipoprotein L1 Polymorphism in Renal Parenchymal Scarring Following Febrile Urinary Tract Infection in Nigerian Under-Five Children: Proposal for a Case-Control Association Study.JMIR research protocols · 2018Article
- Application of next-generation sequencing technology to diagnosis and treatment of focal segmental glomerulosclerosis.Clinical and experimental nephrology · 2018Review
- Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry.Current opinion in pediatrics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
Abstract
Single nucleotide polymorphisms (SNPs) in MYH9 and APOL1 on chromosome 22 (c22) are powerfully associated with non-diabetic end-stage renal disease (ESRD) in African Americans (AAs). Many AAs diagnosed with type 2 diabetic nephropathy (T2DN) have non-diabetic kidney disease, potentially masking detection of DN genes. Therefore, genome-wide association analyses were performed using the Affymetrix SNP Array 6.0 in 966 AA with T2DN and 1,032 non-diabetic, non-nephropathy (NDNN) controls, with and without adjustment for c22 nephropathy risk variants. No associations were seen between FRMD3 SNPs and T2DN before adjusting for c22 variants. However, logistic regression analysis revealed seven FRMD3 SNPs significantly interacting with MYH9-a finding replicated in 640 additional AA T2DN cases and 683 NDNN controls. Contrasting all 1,592 T2DN cases with all 1,671 NDNN controls, FRMD3 SNPs appeared to interact with the MYH9 E1 haplotype (e.g., rs942280 interaction p-value = 9.3E⁻⁷ additive; odds ratio [OR] 0.67). FRMD3 alleles were associated with increased risk of T2DN only in subjects lacking two MYH9 E1 risk haplotypes (rs942280 OR = 1.28), not in MYH9 E1 risk allele homozygotes (rs942280 OR = 0.80; homogeneity p-value = 4.3E⁻⁴). Effects were weaker stratifying on APOL1. FRMD3 SNPS were associated with T2DN, not type 2 diabetes per se, comparing AAs with T2DN to those with diabetes lacking nephropathy. T2DN-associated FRMD3 SNPs were detectable in AAs only after accounting for MYH9, with differential effects for APOL1. These analyses reveal a role for FRMD3 in AA T2DN susceptibility and accounting for c22 nephropathy risk variants can assist in detecting DN susceptibility genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.